Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities researchers at Leerink Partners from a “market perform” rating to an “outperform” rating in a report issued on Wednesday,Finviz reports. The firm currently has a $834.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $762.00. Leerink Partners’ target price suggests a potential upside of 19.65% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $982.43.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $697.05 on Wednesday. The stock has a market cap of $76.60 billion, a price-to-earnings ratio of 17.25, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company’s fifty day moving average is $719.16 and its 200 day moving average is $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the business posted $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.75 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Mizuho Securities USA LLC raised its holdings in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $1,334,000. Finally, Golden State Equity Partners increased its holdings in Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.